Premium
Treatment using tadalafil for severe pre‐eclampsia with fetal growth restriction
Author(s) -
Tanaka Hiroaki,
Kubo Michiko,
Nii Masafumi,
Maki Sintarou,
Umekawa Takashi,
Ikeda Tomoaki
Publication year - 2017
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.13335
Subject(s) - tadalafil , medicine , pregnancy , fetal growth , intrauterine growth restriction , eclampsia , gestation , fetus , obstetrics , placenta , proteinuria , gynecology , sildenafil , genetics , biology , kidney
For severe pre‐eclampsia (PE) with fetal growth restriction (FGR), the only effective treatment is early delivery of the placenta. Clinicians are often forced to end the pregnancy because of maternal indications. We report a case of severe PE with FGR in which the PE was temporarily improved and pregnancy successfully prolonged with tadalafil, a phosphodiesterase 5 inhibitor. A 35‐year‐old primigravid woman presented at 27 3/7 weeks of gestation with severe PE and FGR. After commencing tadalafil administration, biochemical and angiogenic markers improved. Thereafter, hypertension and proteinuria temporarily improved. Importantly, the pregnancy was prolonged by 14 days after the initiation of tadalafil administration. Tadalafil may be a novel treatment for severe PE with FGR to prolong pregnancy.